We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+16.1%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.69B
AUM Growth
+$3.31M
Cap. Flow
-$43.7M
Cap. Flow %
-2.58%
Top 10 Hldgs %
77.31%
Holding
52
New
6
Increased
5
Reduced
4
Closed
15

Top Buys

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$86.1M
2
ZYME icon
Zymeworks
ZYME
+$68M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$23.6M
4
ALKS icon
Alkermes
ALKS
+$14.9M
5
VRNA
Verona Pharma
VRNA
+$14.8M

Top Sells

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$143M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$82.5M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$12.1M
4
BEAM icon
Beam Therapeutics
BEAM
+$10.3M
5
DNA icon
Ginkgo Bioworks
DNA
+$8.34M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Miscellaneous 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZYME icon
1
Zymeworks
ZYME
$2.02B
$288M 17.06%
22,970,388
+5,710,840
+33% +$68M
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
$206M 12.19%
11,895,808
– –
JAZZ icon
3
Jazz Pharmaceuticals
JAZZ
$15.9B
$181M 10.72%
1,706,469
– –
ANAB icon
4
AnaptysBio
ANAB
$1.67B
$175M 10.36%
7,880,094
– –
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$9B
$123M 7.3%
4,288,120
– –
ITOS
6
DELISTED
iTeos Therapeutics
ITOS
$107M 6.31%
+10,688,978
New +$86.1M
CRSP icon
7
CRISPR Therapeutics
CRSP
$5.58B
$67.6M 4%
1,389,276
– –
QURE icon
8
uniQure
QURE
$3.38B
$55.6M 3.29%
3,988,971
– –
TNGX icon
9
Tango Therapeutics
TNGX
$3.94B
$54.4M 3.22%
10,630,736
– –
XNCR icon
10
Xencor
XNCR
$1.94B
$48.3M 2.86%
6,144,767
– –
IMNM icon
11
Immunome
IMNM
$3.13B
$37.9M 2.25%
4,079,415
– –
JANX icon
12
Janux Therapeutics
JANX
$1.1B
$34M 2.01%
1,469,818
– –
LKFT
13
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$29M 1.72%
1,036,945
+881,939
+569% +$23.6M
ETON icon
14
Eton Pharmaceutcials
ETON
$1.71B
$28.9M 1.71%
2,030,544
+91,256
+5% +$1.44M
KURA icon
15
Kura Oncology
KURA
$1.13B
$24.2M 1.43%
4,200,000
+1,559,702
+59% +$9.56M
AKRO
16
DELISTED
Akero Therapeutics
AKRO
$23.5M 1.39%
440,000
– –
MDGL icon
17
Madrigal Pharmaceuticals
MDGL
$12.3B
$22.7M 1.34%
75,000
– –
NGNE icon
18
Neurogene
NGNE
$732M
$19M 1.13%
1,271,342
– –
VRNA
19
DELISTED
Verona Pharma
VRNA
$18.9M 1.12%
+200,000
New +$14.8M
TECX
20
Tectonic Therapeutic
TECX
$696M
$18.6M 1.1%
935,121
– –
ORIC icon
21
Oric Pharmaceuticals
ORIC
$1.37B
$16.4M 0.97%
1,618,068
-1,800,000
-53% -$12.1M
ALKS icon
22
Alkermes
ALKS
$7.95B
$14.3M 0.85%
+500,000
New +$14.9M
RNAM
23
DELISTED
Avidity Biosciences
RNAM
$14.2M 0.84%
500,000
-57,576
-10% -$1.72M
MBX
24
MBX Biosciences
MBX
$3.03B
$13.1M 0.78%
1,149,794
-109,479
-9% -$1.12M
VYGR icon
25
Voyager Therapeutics
VYGR
$218M
$12.2M 0.72%
3,917,546
– –
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2025 Portfolio in Review

As of Q2 2025, EcoR1 Capital held 52 positions worth $1.69B, up 0.2% from $1.69B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

EcoR1 Capital's Q2 2025 filing shows 6 new, 5 increased, 4 reduced and 15 closed positions. Its largest new stake was iTeos Therapeutics: 10,688,978 shares worth $107M. The largest sale was Prothena Corp, an estimated $143M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q2 2025 buy was iTeos Therapeutics: 10,688,978 shares worth $107M.
  • EcoR1 Capital added most to Zymeworks in Q2 2025, an estimated $68M increase.
  • EcoR1 Capital's biggest Q2 2025 reduction was Oric Pharmaceuticals, cutting an estimated $12.1M.
  • EcoR1 Capital fully exited Prothena Corp in Q2 2025, selling an estimated $143M.
  • EcoR1 Capital's ten largest holdings make up 77% of its $1.69B portfolio in Q2 2025.
  • EcoR1 Capital opened 6 new positions and closed 15 in Q2 2025.
  • EcoR1 Capital's portfolio value rose 0.2% quarter-over-quarter to $1.69B.

Based on EcoR1 Capital's 13F filing for Q2 2025, filed 14 Aug 2025.